listings

Biotech firms switch listings from Nasdaq to HKEX

Hong Kong-listed biotech firms are outperforming as Trump’s policies cause firms to change course from their traditional US destination, with more HKEX listings expected in the second half of 2025; experts shared their views at BIOHK.
September 23, 2025

When the SPACs come marching into Asia

The rapid pace at which special purpose acquisition companies (SPACs) are raising money is putting regulators across the region in a quandary: either further accommodate an unproven investment structure or risk being left behind.
March 30, 2021